Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

4 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

4 recruiting4 with results

Enrollment Performance

Analytics

Phase 2

5(50.0%)

Phase 3

2(20.0%)

Phase 4

2(20.0%)

Phase 1

1(10.0%)

10Total

Phase 2(5)

Phase 3(2)

Phase 4(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT06849544Phase 2Recruiting

Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection

Role: collaborator

NCT07469202Phase 4Not Yet Recruiting

CYTALUX Dose Extension Study

Role: lead

NCT06434909Phase 2Completed

CYTALUX™for the Intraoperative Imaging of Prostate Cancer

Role: collaborator

NCT07039526Phase 2Recruiting

Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.

Role: collaborator

NCT07124351Phase 4Recruiting

Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)

Role: collaborator

NCT06235125Phase 1Recruiting

Safety and Feasibility of Intraoperative Visualization With Cytalux in Children

Role: collaborator

NCT02872701Phase 2Completed

OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules

Role: lead

NCT04241315Phase 3Completed

ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting

Role: lead

NCT02317705Phase 2Completed

Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

Role: lead

NCT03180307Phase 3Completed

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Role: lead

All 10 trials loaded